Overview

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Status:
Active, not recruiting
Trial end date:
2022-10-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether daily treatment with apalutamide affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC)
Phase:
Phase 1
Details
Lead Sponsor:
Aragon Pharmaceuticals, Inc.